Belief BioMed is an innovative biopharmaceutical company focused on the development of gene therapies. BBM-D101 is a recombinant adeno-associated virus (rAAV) gene therapy product independently developed by Belief BioMed with proprietary intellectual property rights. Administered via a single intravenous infusion, it utilizes an engineered rAAV vector to deliver an optimized gene expression cassette to muscles throughout the body, with the aim of achieving durable therapeutic efficacy for Duchenne muscular dystrophy (DMD) following a single administration.

Belief BioMed does not currently accept expanded access (compassionate use) requests for this product (BBM-D101) on a global basis. We encourage interested patients to gain access to this investigational therapy by participating in ongoing clinical trials. Patients may discuss the details of the trials with their primary care physician or visit https://clinicaltrials.gov and search by keyword "NCT07058662", company name "Belief BioMed" or drug name "BBM-D101" , or visit our corporate website at https://www.beliefbiomed.com for more information.

Should you have further questions, please consult your physician or contact us at: DMDclinicaltrial@beliefbiomed.com.

Belief BioMed will update this policy from time to time in accordance with the U.S. 21st Century Cures Act and other applicable laws and regulations.

Date of Issuance: August 19, 2026